Pub Date : 2023-08-01DOI: 10.30699/jambs.31.147.391
Ali Heidari, Gholamhosein Meftahi, Farideh Bahrami, Zahra Bahari, Ali Zarei Mahmoudabadi, Hasan Fallah Huseini, Zohreh Jangravi
{"title":"Anti-Adipogenic Effects of <i>Eryngium billardieri</i> Extract during 3T3-L1 Adipocyte Differentiation","authors":"Ali Heidari, Gholamhosein Meftahi, Farideh Bahrami, Zahra Bahari, Ali Zarei Mahmoudabadi, Hasan Fallah Huseini, Zohreh Jangravi","doi":"10.30699/jambs.31.147.391","DOIUrl":"https://doi.org/10.30699/jambs.31.147.391","url":null,"abstract":"","PeriodicalId":36550,"journal":{"name":"Journal of Advances in Medical and Biomedical Research","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135054476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-01DOI: 10.30699/jambs.31.147.381
Zainab Jumaah Fadhil, Ahmed Abdul- Hassan Abbas, Mohammad Hadi Al-Osami
{"title":"The Influence of TNFRSF1B, PADI4, and miRNA 499 Gene Polymorphisms on Susceptibility and Responsiveness to TNF Inhibitors in Patients with Rheumatoid Arthritis","authors":"Zainab Jumaah Fadhil, Ahmed Abdul- Hassan Abbas, Mohammad Hadi Al-Osami","doi":"10.30699/jambs.31.147.381","DOIUrl":"https://doi.org/10.30699/jambs.31.147.381","url":null,"abstract":"","PeriodicalId":36550,"journal":{"name":"Journal of Advances in Medical and Biomedical Research","volume":"118 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135054486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-01DOI: 10.30699/jambs.31.147.323
Sara Kaedi, Amin Kordi Yoosefinejad, Alireza Motealleh, Sobhan Sobhani
{"title":"The Immediate Effects of Spiral Kinesio Taping on In-toeing Gait Pattern in Children with Spastic Diplegic Cerebral Palsy","authors":"Sara Kaedi, Amin Kordi Yoosefinejad, Alireza Motealleh, Sobhan Sobhani","doi":"10.30699/jambs.31.147.323","DOIUrl":"https://doi.org/10.30699/jambs.31.147.323","url":null,"abstract":"","PeriodicalId":36550,"journal":{"name":"Journal of Advances in Medical and Biomedical Research","volume":"36 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135054488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.30699/jambs.31.146.221
Behzad Imani, Hamidreza Nejati, A. Sepidkar, E. Talebi-Ghane
10.30699/jambs.31.146.221 Background & Objective: Although the pain severity following laparoscopic cholecystectomy is generally lower compared to the open method, but some patients may still experience abdominal and shoulder pain for several days after the laparoscopic procedure. Based on recent evidences, pneumoperitoneum using low-pressure carbon dioxide gas can reduce the pain. This study evaluated the feedback on shoulder pain severity from laparoscopic cholecystectomy patients experiencing CO2-pneumoperitoneum. Materials & Methods: 80 laparoscopic cholecystectomy cases were allocated for intervention (n = 40) and control groups (n = 40) randomly. Pneumoperitoneum was done by a direct trocar. Patients’ pain feedback was assessed using the visual pain scale after the surgery. SPSS 21 was used to analyze the collected data. Results: Shoulder pain frequency significantly differed between the two groups at 12 hours (P = 0.048) and 24 hours (P = 0.001) after the surgery. Regarding average shoulder pain severity, the groups showed significant differences after 2, 6, and 24 hours of surgery (P < 0.05). Moreover, pneumoperitoneum duration was different in the groups (P = 0.001). Conclusion: Based on these findings, low pressure of pneumoperitoneum with active evacuation compared to the standard pressure, efficiently reduced shoulder pain intensity. Thus, using low-pressure pneumoperitoneum in laparoscopic cholecystectomy is recommended to relieve postoperative pain.
{"title":"The Effect of Low-Pressure Pneumoperitoneum with Active Evacuation on the Severity of Shoulder Pain in Patients Undergoing Laparoscopic Cholecystectomy","authors":"Behzad Imani, Hamidreza Nejati, A. Sepidkar, E. Talebi-Ghane","doi":"10.30699/jambs.31.146.221","DOIUrl":"https://doi.org/10.30699/jambs.31.146.221","url":null,"abstract":"10.30699/jambs.31.146.221 Background & Objective: Although the pain severity following laparoscopic cholecystectomy is generally lower compared to the open method, but some patients may still experience abdominal and shoulder pain for several days after the laparoscopic procedure. Based on recent evidences, pneumoperitoneum using low-pressure carbon dioxide gas can reduce the pain. This study evaluated the feedback on shoulder pain severity from laparoscopic cholecystectomy patients experiencing CO2-pneumoperitoneum. Materials & Methods: 80 laparoscopic cholecystectomy cases were allocated for intervention (n = 40) and control groups (n = 40) randomly. Pneumoperitoneum was done by a direct trocar. Patients’ pain feedback was assessed using the visual pain scale after the surgery. SPSS 21 was used to analyze the collected data. Results: Shoulder pain frequency significantly differed between the two groups at 12 hours (P = 0.048) and 24 hours (P = 0.001) after the surgery. Regarding average shoulder pain severity, the groups showed significant differences after 2, 6, and 24 hours of surgery (P < 0.05). Moreover, pneumoperitoneum duration was different in the groups (P = 0.001). Conclusion: Based on these findings, low pressure of pneumoperitoneum with active evacuation compared to the standard pressure, efficiently reduced shoulder pain intensity. Thus, using low-pressure pneumoperitoneum in laparoscopic cholecystectomy is recommended to relieve postoperative pain.","PeriodicalId":36550,"journal":{"name":"Journal of Advances in Medical and Biomedical Research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45743420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.30699/jambs.31.146.275
Ali Faghih Habibi, Sevil Nasirmohtaram, S. Nemati, Ehsan Kazemnezhad Leyli, M. Akbarpour, Hedieh Ramezani, Rastin Hosseinzadeh Asli
10.30699/
10.30699 /
{"title":"Disorders of the Septum and Lateral Nasal Wall in Candidates for Septorhinoplasty: A Study in a University Hospital in Rasht, Northern Iran","authors":"Ali Faghih Habibi, Sevil Nasirmohtaram, S. Nemati, Ehsan Kazemnezhad Leyli, M. Akbarpour, Hedieh Ramezani, Rastin Hosseinzadeh Asli","doi":"10.30699/jambs.31.146.275","DOIUrl":"https://doi.org/10.30699/jambs.31.146.275","url":null,"abstract":"10.30699/","PeriodicalId":36550,"journal":{"name":"Journal of Advances in Medical and Biomedical Research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47116196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.30699/jambs.31.146.250
Z. Soleimani, A. Laluie, Arman Jenab, A. Soleimani
10.30699/jambs.31.146.250 Background & Objective: Given the importance of the benefits of natural childbirth and the complications of recurrent cesarean section, we have conducted the present study to determine the maternal and neonatal complications of natural childbirth after cesarean section. Materials & Methods: In this case-control study, the obstetric complications of 84 women who had undergone a previous cesarean delivery referred to Baqiyatallah Hospital in 2018 for vaginal delivery after cesarean section (VBAC) delivery compared with 84 women with a previous vaginal delivery, who intended to give birth vaginally for the second delivery. Demographic, anthropometric, obstetric, and perinatal data of them were collected and registered in a researcher-developed form. Two groups were compared using the t-test and chi-square test. Results: The mean age in VBAC and control group was 30.49±6.83 and 32.08±7.28 years, respectively (P=0.15). There were not any occurrence of urinary rupture, bladder rupture, stool control disorder, uterine rupture, nephrotic infection, and ICU hospitalization of the mothers in the two groups. Regarding puerperal infection (3.57% in the VBAC group and 4.76% in the control group, P=0.69) and hospitalization of neonates in ICU (9.52% in the VBAC group and 5.95% in the control group, p=0.39), there was no significant difference between the two groups. Conclusion: It seems that the overall incidence of obstetric complications in women attempting vaginal birth after cesarean delivery is low and not higher than those with prior vaginal delivery. Therefore, for the achievement of benefits of natural childbirth for both the mother and the fetus, women with a prior cesarean should be offered VBAC.
{"title":"Obstetric Outcomes of Vaginal Birth After Cesarean Section: A Case-Control Study","authors":"Z. Soleimani, A. Laluie, Arman Jenab, A. Soleimani","doi":"10.30699/jambs.31.146.250","DOIUrl":"https://doi.org/10.30699/jambs.31.146.250","url":null,"abstract":"10.30699/jambs.31.146.250 Background & Objective: Given the importance of the benefits of natural childbirth and the complications of recurrent cesarean section, we have conducted the present study to determine the maternal and neonatal complications of natural childbirth after cesarean section. Materials & Methods: In this case-control study, the obstetric complications of 84 women who had undergone a previous cesarean delivery referred to Baqiyatallah Hospital in 2018 for vaginal delivery after cesarean section (VBAC) delivery compared with 84 women with a previous vaginal delivery, who intended to give birth vaginally for the second delivery. Demographic, anthropometric, obstetric, and perinatal data of them were collected and registered in a researcher-developed form. Two groups were compared using the t-test and chi-square test. Results: The mean age in VBAC and control group was 30.49±6.83 and 32.08±7.28 years, respectively (P=0.15). There were not any occurrence of urinary rupture, bladder rupture, stool control disorder, uterine rupture, nephrotic infection, and ICU hospitalization of the mothers in the two groups. Regarding puerperal infection (3.57% in the VBAC group and 4.76% in the control group, P=0.69) and hospitalization of neonates in ICU (9.52% in the VBAC group and 5.95% in the control group, p=0.39), there was no significant difference between the two groups. Conclusion: It seems that the overall incidence of obstetric complications in women attempting vaginal birth after cesarean delivery is low and not higher than those with prior vaginal delivery. Therefore, for the achievement of benefits of natural childbirth for both the mother and the fetus, women with a prior cesarean should be offered VBAC.","PeriodicalId":36550,"journal":{"name":"Journal of Advances in Medical and Biomedical Research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47327510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.30699/jambs.31.146.244
Omalbanin Mokhlesi, M. Sadeghian, A. Shajiei, M. Sheikhi, Payam Siyadat, M. Kooshyar, H. Rahimi, N. Amini, Maliheh Dadgar Moghadam, H. Ayatollahi, S. Shams, Zahra Khoshnegah
10.30699/jambs.31.146.244 Background & Objective: Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by an aberrant BCR-ABL fusion protein. Imatinib mesylate (IM) is a tyrosine kinase inhibitor that induces clinical remissions in chronic-phase CML patients. The T315I mutation at the gatekeeper residues of BCR-ABL confers resistance to both IM and second-generation TKIs, including dasatinib and nilotinib. Our objective was to determine the prevalence of T315I mutation between two groups of CML patients before and during Imatinib treatment in North-East of Iran. Materials & Methods: This study was conducted on 100 newly diagnosed cases of CML (before commencing IM treatment) and 25 IM-resistant CML patients. PCR-RFLP, ASO-PCR, and direct sequencing were performed to detect T315I mutations. Results: The median age of newly-diagnosed and IM-resistant patients was 48±14 and 50±12.3 years, respectively. Males/Females ratio was 1 and 1.08 for newly diagnosed and IM-resistant patients, respectively. There was no significant difference regarding the age and sex between the two groups. During the study, T315I mutational analysis was performed for all 125 patients. The prevalence of T315I mutation was 0% and 4% for newly-diagnosed and IM-resistant patients, respectively. T315I mutation was not detected before IM administration, although it was detected in 1(4%) among resistant patients who were at least 6-months on IM treatment. Conclusion: These observations suggest that T315I mutation may be categorized as secondary resistance and induce clonal expansion due to BCR/ABL instability. Hence, BCR-ABL mutations are less likely to appear before the onset of treatment, as presented in our study.
{"title":"Frequency of T315I Mutation in Patients with Chronic Myeloid Leukemia Before and During Imatinib Treatment: A Study in North-East of Iran","authors":"Omalbanin Mokhlesi, M. Sadeghian, A. Shajiei, M. Sheikhi, Payam Siyadat, M. Kooshyar, H. Rahimi, N. Amini, Maliheh Dadgar Moghadam, H. Ayatollahi, S. Shams, Zahra Khoshnegah","doi":"10.30699/jambs.31.146.244","DOIUrl":"https://doi.org/10.30699/jambs.31.146.244","url":null,"abstract":"10.30699/jambs.31.146.244 Background & Objective: Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by an aberrant BCR-ABL fusion protein. Imatinib mesylate (IM) is a tyrosine kinase inhibitor that induces clinical remissions in chronic-phase CML patients. The T315I mutation at the gatekeeper residues of BCR-ABL confers resistance to both IM and second-generation TKIs, including dasatinib and nilotinib. Our objective was to determine the prevalence of T315I mutation between two groups of CML patients before and during Imatinib treatment in North-East of Iran. Materials & Methods: This study was conducted on 100 newly diagnosed cases of CML (before commencing IM treatment) and 25 IM-resistant CML patients. PCR-RFLP, ASO-PCR, and direct sequencing were performed to detect T315I mutations. Results: The median age of newly-diagnosed and IM-resistant patients was 48±14 and 50±12.3 years, respectively. Males/Females ratio was 1 and 1.08 for newly diagnosed and IM-resistant patients, respectively. There was no significant difference regarding the age and sex between the two groups. During the study, T315I mutational analysis was performed for all 125 patients. The prevalence of T315I mutation was 0% and 4% for newly-diagnosed and IM-resistant patients, respectively. T315I mutation was not detected before IM administration, although it was detected in 1(4%) among resistant patients who were at least 6-months on IM treatment. Conclusion: These observations suggest that T315I mutation may be categorized as secondary resistance and induce clonal expansion due to BCR/ABL instability. Hence, BCR-ABL mutations are less likely to appear before the onset of treatment, as presented in our study.","PeriodicalId":36550,"journal":{"name":"Journal of Advances in Medical and Biomedical Research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69575353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.30699/jambs.31.146.255
F. Najari, A. Setayesh, E. Gopinath, S. Mirzaei
10.30699/jambs.31.146.255 Background & Objective: Breast cancer (BC) is the leading cause of cancer mortality among women in different countries around the world, including India. Monoclonal antibodies (MoAbs) have emerged as a promising targeted treatment for BC, improving the survival rate of these patients with minimum adverse effects. This study aimed to investigate the severity of the adverse effects of MoAbs in an Indian population. Materials & Methods: This longitudinal descriptive study was conducted on 120 BC patients over six months in a tertiary care hospital in Bangalore, India, in 2020. A data collection form was used to gather relevant data. The collected data were analyzed by SPSS Version 21, using Chi-square and Fisher’s exact tests. A P-value less than 0.05 was considered statistically significant. Results: Among 97 patients evaluated in this study (including 29 patients in the non-exposed group), the adverse effects of BC were observed in all age groups. Most adverse effects were attributed to trastuzumab (37.50%; CI: 31.6-44) and bevacizumab (26.78%; CI: 20.9-31.8). The MoAbs were well tolerated by the patients, causing minimum adverse effects that were manageable by supportive therapy. Anemia was the most prevalent adverse effect. Evaluation of the null hypothesis indicated that the adverse effects of MoAbs depended on their amount and composition. The results of analysis using the Naranjo scale revealed that most of the adverse effects were probable (67%) and possible (32%), respectively. Also, according to the WHO scale, most of the adverse effects were under the categories of probable (61.20%) and possible (38.14%), respectively. Conclusion: Based on the present results, the adverse effects of MoAbs were manageable by supportive care. Anemia was found to be the most prevalent adverse effect. Meanwhile, no potential adverse cardiovascular event was observed in patients on trastuzumab, except one case of dilated cardiomyopathy.
10.30699/jamms.31.46.255背景与目的：癌症（BC）是包括印度在内的世界各国癌症妇女死亡的主要原因。单克隆抗体（MoAbs）已成为BC的一种很有前途的靶向治疗方法，可以提高这些患者的生存率，并将不良反应降至最低。本研究旨在调查MoAbs在印度人群中不良反应的严重程度。材料与方法：这项纵向描述性研究于2020年在印度班加罗尔的一家三级护理医院对120名BC患者进行了为期六个月的研究。数据收集表用于收集相关数据。收集的数据采用SPSS Version 21进行分析，采用卡方检验和Fisher精确检验。P值小于0.05被认为具有统计学意义。结果：在本研究评估的97名患者中（包括29名非暴露组患者），所有年龄组都观察到BC的不良反应。大多数不良反应归因于曲妥珠单抗（37.50%；CI：31.6-44）和贝伐单抗（26.78%；CI：20.9-31.8）。MoAbs患者耐受性良好，造成的不良反应最小，可通过支持性治疗进行控制。贫血是最常见的不良反应。对无效假设的评估表明，MoAbs的不良影响取决于其数量和成分。使用Naranjo量表的分析结果显示，大多数不良反应分别是可能的（67%）和可能的（32%）。此外，根据世界卫生组织的量表，大多数不良反应分别属于可能（61.20%）和可能（38.14%）两类。结论：根据目前的结果，MoAbs的不良反应可以通过支持性护理来控制。贫血被发现是最普遍的不良反应。同时，除了一例扩张型心肌病外，在服用曲妥珠单抗的患者中未观察到潜在的心血管不良事件。
{"title":"Evaluation of the Adverse Effects of Monoclonal Antibodies in Breast Cancer Treatment in a Tertiary Care Hospital in Bengaluru, India, in 2020","authors":"F. Najari, A. Setayesh, E. Gopinath, S. Mirzaei","doi":"10.30699/jambs.31.146.255","DOIUrl":"https://doi.org/10.30699/jambs.31.146.255","url":null,"abstract":"10.30699/jambs.31.146.255 Background & Objective: Breast cancer (BC) is the leading cause of cancer mortality among women in different countries around the world, including India. Monoclonal antibodies (MoAbs) have emerged as a promising targeted treatment for BC, improving the survival rate of these patients with minimum adverse effects. This study aimed to investigate the severity of the adverse effects of MoAbs in an Indian population. Materials & Methods: This longitudinal descriptive study was conducted on 120 BC patients over six months in a tertiary care hospital in Bangalore, India, in 2020. A data collection form was used to gather relevant data. The collected data were analyzed by SPSS Version 21, using Chi-square and Fisher’s exact tests. A P-value less than 0.05 was considered statistically significant. Results: Among 97 patients evaluated in this study (including 29 patients in the non-exposed group), the adverse effects of BC were observed in all age groups. Most adverse effects were attributed to trastuzumab (37.50%; CI: 31.6-44) and bevacizumab (26.78%; CI: 20.9-31.8). The MoAbs were well tolerated by the patients, causing minimum adverse effects that were manageable by supportive therapy. Anemia was the most prevalent adverse effect. Evaluation of the null hypothesis indicated that the adverse effects of MoAbs depended on their amount and composition. The results of analysis using the Naranjo scale revealed that most of the adverse effects were probable (67%) and possible (32%), respectively. Also, according to the WHO scale, most of the adverse effects were under the categories of probable (61.20%) and possible (38.14%), respectively. Conclusion: Based on the present results, the adverse effects of MoAbs were manageable by supportive care. Anemia was found to be the most prevalent adverse effect. Meanwhile, no potential adverse cardiovascular event was observed in patients on trastuzumab, except one case of dilated cardiomyopathy.","PeriodicalId":36550,"journal":{"name":"Journal of Advances in Medical and Biomedical Research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46061093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.30699/jambs.31.146.210
M. Shojaeifard, H. Ahangar, Sepehr Gohari, M. Oveisi, Majid Maleki, Tara Reshadmanesh, Shahram Arsang-Jang, Mahsa Mahjani, Mozhgan Pourkeshavarz, G. Hajianfar, S. Mazloomzadeh, Isaac Shiri, Sheida Gohari
10.30699
10.30699
{"title":"Assessment of Machine Learning Approaches to Predict in-Hospital Mortality in Patients Underwent Prosthetic Heart Valve Replacement Surgery","authors":"M. Shojaeifard, H. Ahangar, Sepehr Gohari, M. Oveisi, Majid Maleki, Tara Reshadmanesh, Shahram Arsang-Jang, Mahsa Mahjani, Mozhgan Pourkeshavarz, G. Hajianfar, S. Mazloomzadeh, Isaac Shiri, Sheida Gohari","doi":"10.30699/jambs.31.146.210","DOIUrl":"https://doi.org/10.30699/jambs.31.146.210","url":null,"abstract":"10.30699","PeriodicalId":36550,"journal":{"name":"Journal of Advances in Medical and Biomedical Research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45148752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-01DOI: 10.30699/jambs.31.146.238
Seyyed Gholamreza Mortazavi Moghadam, A. Zarban, Reza Yaghobbi Marakieh, E. Allahyari
10.30699/jambs.31.146.238 Background & Objective: Chronic inflammation, dyspnea and activity limitation are common phenomena in patients with chronic obstructive lung disease. Clinical studies suggest that Ubiquinone has anti-inflammatory and energetic properties. Here the beneficial effect of CoQ10 in patients with COPD will be studied. Materials & Methods: Baesd on the census method, 90 patients with moderate to severe COPD were divided into two identical placebo and CoQ10 groups. High sensitive-C-reactive protein (hs-CRP), Forced Expiratory Volume in 1 second, numerical rating breathlessness scale and "the time to get exhausted" were evaluated and recorded at baseline and the end of the study. The CoQ10 group received 120 mg of CoQ10 supplement per day versus the placebo group who also received a placebo (identical in look, size and taste to pharmaceutical sample) and were followed for 6 weeks. Data were analyzed using t-test, and nonparametric statistical tests. Qualitative variables were assessed by chi-square or Fisher exact tests. Results: The study included 49(53.6%) women and 41(46.4%) men, collectively 90 patients with moderate to severe COPD. The mean age was 66.97±12.59 years in the placebo and 64.21±11.78 years in the CoQ10 group (p=0.30). Breathlessness scale was improved in CoQ10 group (p<0.001). hs-CRP significantly declined after intervention in the CoQ10 compared to the placebo group (p<0.001).No serious side effects were observed as a result of CoQ10 consumption. Conclusion: Daily administration of CoQ10 in COPD patients increases hs-CRP and improves dyspnea and "the time to get exhausted” without side effect.
{"title":"Some Beneficial Effects of Coenzyme Q10 Supplementation on Patients with Chronic Obstructive Pulmonary Disease","authors":"Seyyed Gholamreza Mortazavi Moghadam, A. Zarban, Reza Yaghobbi Marakieh, E. Allahyari","doi":"10.30699/jambs.31.146.238","DOIUrl":"https://doi.org/10.30699/jambs.31.146.238","url":null,"abstract":"10.30699/jambs.31.146.238 Background & Objective: Chronic inflammation, dyspnea and activity limitation are common phenomena in patients with chronic obstructive lung disease. Clinical studies suggest that Ubiquinone has anti-inflammatory and energetic properties. Here the beneficial effect of CoQ10 in patients with COPD will be studied. Materials & Methods: Baesd on the census method, 90 patients with moderate to severe COPD were divided into two identical placebo and CoQ10 groups. High sensitive-C-reactive protein (hs-CRP), Forced Expiratory Volume in 1 second, numerical rating breathlessness scale and \"the time to get exhausted\" were evaluated and recorded at baseline and the end of the study. The CoQ10 group received 120 mg of CoQ10 supplement per day versus the placebo group who also received a placebo (identical in look, size and taste to pharmaceutical sample) and were followed for 6 weeks. Data were analyzed using t-test, and nonparametric statistical tests. Qualitative variables were assessed by chi-square or Fisher exact tests. Results: The study included 49(53.6%) women and 41(46.4%) men, collectively 90 patients with moderate to severe COPD. The mean age was 66.97±12.59 years in the placebo and 64.21±11.78 years in the CoQ10 group (p=0.30). Breathlessness scale was improved in CoQ10 group (p<0.001). hs-CRP significantly declined after intervention in the CoQ10 compared to the placebo group (p<0.001).No serious side effects were observed as a result of CoQ10 consumption. Conclusion: Daily administration of CoQ10 in COPD patients increases hs-CRP and improves dyspnea and \"the time to get exhausted” without side effect.","PeriodicalId":36550,"journal":{"name":"Journal of Advances in Medical and Biomedical Research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42400643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：